AKYA vs. SEER, PRLD, ATHA, BNGO, PRE, STRO, NAUT, TELA, SYRS, and ELMD
Should you be buying Akoya Biosciences stock or one of its competitors? The main competitors of Akoya Biosciences include Seer (SEER), Prelude Therapeutics (PRLD), Athira Pharma (ATHA), Bionano Genomics (BNGO), Prenetics Global (PRE), Sutro Biopharma (STRO), Nautilus Biotechnology (NAUT), TELA Bio (TELA), Syros Pharmaceuticals (SYRS), and Electromed (ELMD). These companies are all part of the "medical" sector.
Seer (NASDAQ:SEER) and Akoya Biosciences (NASDAQ:AKYA) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their media sentiment, valuation, dividends, community ranking, institutional ownership, analyst recommendations, risk, earnings and profitability.
In the previous week, Akoya Biosciences had 5 more articles in the media than Seer. MarketBeat recorded 15 mentions for Akoya Biosciences and 10 mentions for Seer. Akoya Biosciences' average media sentiment score of -0.18 beat Seer's score of -0.23 indicating that Seer is being referred to more favorably in the media.
Akoya Biosciences received 25 more outperform votes than Seer when rated by MarketBeat users. Likewise, 60.87% of users gave Akoya Biosciences an outperform vote while only 14.29% of users gave Seer an outperform vote.
Akoya Biosciences has higher revenue and earnings than Seer. Akoya Biosciences is trading at a lower price-to-earnings ratio than Seer, indicating that it is currently the more affordable of the two stocks.
Seer has a beta of 1.52, meaning that its stock price is 52% more volatile than the S&P 500. Comparatively, Akoya Biosciences has a beta of 1.52, meaning that its stock price is 52% more volatile than the S&P 500.
75.2% of Seer shares are owned by institutional investors. Comparatively, 79.4% of Akoya Biosciences shares are owned by institutional investors. 15.0% of Seer shares are owned by company insiders. Comparatively, 7.3% of Akoya Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
Akoya Biosciences has a net margin of -72.68% compared to Akoya Biosciences' net margin of -529.52%. Akoya Biosciences' return on equity of -20.69% beat Seer's return on equity.
Seer currently has a consensus target price of $7.00, suggesting a potential upside of 231.75%. Akoya Biosciences has a consensus target price of $7.79, suggesting a potential upside of 179.06%. Given Akoya Biosciences' higher probable upside, research analysts clearly believe Seer is more favorable than Akoya Biosciences.
Summary
Akoya Biosciences beats Seer on 9 of the 17 factors compared between the two stocks.
Get Akoya Biosciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for AKYA and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding AKYA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Akoya Biosciences Competitors List
Related Companies and Tools
